Melanomas depend on autocrine signals for proliferation and survival; however, no systematic screen of known receptor tyrosine kinases (RTKs) has been performed to identify which autocrine signaling pathways are activated in melanoma. Here, we performed a comprehensive analysis of 42 RTKs in six individual human melanoma tumor specimens as well as 17 melanoma cell lines, some of which were derived from the tumor specimens. We identified five RTKs that were active in almost every one of the melanoma tissue specimens and cell lines, including two previously unreported receptors, insulin-like growth factor receptor 1 (IGF-1R) and macrophage-stimulating protein receptor (MSPR), in addition to three receptors (vascular endothelial growth factor receptor, fibroblast growth factor receptor, and hepatocyte growth factor receptor) known to be autocrine activated in melanoma. We show, by quantitative real time PCR, that all melanoma cell lines expressed genes for the RTK ligands such as HGF, IGF-1, and MSP. Addition of antibodies to either IGF-1 or HGF, but not to MSP, to the culture medium blocked melanoma cell proliferation, and even caused net loss of melanoma cells. Antibody addition deactivated IGF-1R and hepatocyte growth factor receptors, as well as mitogenactivated protein kinase signaling. Thus, IGF-1 is a new growth factor for autocrine driven proliferation of human melanoma in vitro. Our results suggest that IGF-1-IGF-1R autocrine pathway in melanoma is a possible target for therapy in human melanomas. 
Introduction
Melanoma is the leading cause of skin cancer deaths. Once metastatic to distant sites, it is poorly responsive to systemic therapy and is almost always fatal, with an estimated survival of 6-9 months and a 5-year survival rate of less than 5% [1, 2] . Promising melanoma treatment options include those that target cell-signaling pathways critical to melanoma progression and metastasis. Despite their potential, however, most targeted therapies have had limited success in clinical application. This disappointing response profile may be due in part to signaling that allows the cells to resist inhibition of targeted pathways. Alternatively, melanoma cells may be producing and secreting survival and growth factors to activate signaling pathways not yet targeted.
Paracrine and autocrine signaling is mediated through receptor tyrosine kinase (RTK) activation at the cell surface [3] . Paracrine activation of RTKs by stromal growth factors supports melanoma and growth, but autocrine activation of RTKs is of particular interest because this may enable survival during metastatic progression. There are some studies of RTK and growth factor expression in melanoma [4] [5] [6] [7] . Autocrine signaling by fibroblast growth factor (FGF)/FGFR has been described in melanomas, and we have described a vascular endothelial growth factor (VEGF)/VEGFR-2 autocrine growth loop in melanomas [8] [9] [10] [11] [12] [13] . Hepatocyte growth factor (HGF)/HGF receptor (HGFR is also commonly referred to as c-Met) signaling has been implicated in both paracrine and autocrine growth signaling in various tumors and in the development of melanoma [14] [15] [16] . HGF has been identified as an autocrine growth factor in multiple cancers including bladder cancer [17] [18] [19] [20] and has been shown to promote tumorigenesis and tumor cell growth [21, 22] . HGF has also been previously identified as an autocrine factor in malignant melanoma [23] . However, in that study the effects of HGF blockade on cell growth or proliferation were not examined.
The aim of this study was to perform a comprehensive analysis of activated RTKs in melanoma cells and tumors, to identify different RTKs and cognate growth factors, and to determine whether inhibition of these factors could reduce melanoma proliferation and survival.
Methods

Cell culture
Melanoma cell lines used in this study were derived from tumors taken from tumor-involved lymph nodes from patients at the University of Virginia (VMM18, VMM39, VMM5A, VMM15, VMM14, VMM17, and VMM609) or from patients at Duke University (DM6, DM13, DM93, DM122, and DM331) as described previously [24] [25] [26] [27] . VMM1 was derived from a metastatic brain tumor, VMM425 was derived from a pelvic soft tissue recurrence, and VMM917 was derived from a subcutaneous recurrence. These three lines were all derived from patients at the University of Virginia in the same manner as described for cells cultured from lymph nodes [27] . SKMel24 and HT144 were both obtained from American Type Cell Culture. All of the cell lines were cultured in RPMI 1640 medium supplemented with 5% fetal bovine serum (FBS), 2 mmol/l L-glutamine, penicillin (100 units/ml), and streptomycin (100 mg/ml) at 371C in 5% CO 2 , unless otherwise indicated.
Harvesting lysates
For analysis of proteins, cells from all 17 melanoma lines were plated in 100 mm Petri dishes and incubated for 24 h in RPMI medium plus 5% FBS. After 24 h, the medium was aspirated and the cells were washed twice with 10 ml PBS and harvested and lysed as described previously [24] . For serum-starvation lysates, cells were harvested the same way except no serum was added to the media and cells were lysed after 18-24 h. For quick frozen tumor tissue, tumor pieces were placed into small pouches of aluminum foil covered with two layers of polyester freezer labels, kept at -1801C with vapor N 2 . The tumor pieces in packets were placed between two prechilled metal plates, which were placed between two prechilled pieces of wood and mechanically smashed to powder. The tumor powder was placed on wet ice and mixed with lysis buffer [plus 100 ml/10 ml phosphatase inhibitor cocktail (Sigma P2850, Sigma-Aldrich Corp., St Louis, Missouri, USA)] according to tissue weight (approximately 3 ml/mg). Lysates were microfuged and aliquoted. Total protein concentration was determined by bicinchoninic acid and the lysate was kept frozen at -801C.
Phospho receptor tyrosine kinase arrays
Melanoma cells were treated with peroxyvanadate [28] for 30 min before harvest. Media was removed, cells were rinsed with ice cold PBS, trypsinized at room temperature for 1 min, and pelleted by centrifugation at 41C. Cells were lysed with the NP-40 lysis buffer from the R&D Proteome Profiler Arrays Human phospho-RTK array (R&D systems, Minneapolis, Minnesota, USA, Catalog No. ARY001, Lot 1155200). These arrays have immobilized specific antibodies for individual RTKs spotted in duplicate on a filter of the size of a microscope slide ( Fig 
Statistical methods for correlation coefficients
The natural logarithmic transformation of the raw data was used. For each assay (individual/tissue/experiment), the ratios of phosphorylated RTKs to the average of the positive controls, log(phosphorylated RTK)/log(control), were calculated. Correlation plots of the ratios in experiment A and experiment B were produced separately for each individual/tissue subset. Spearman correlations were calculated to summarize the strength of the correlations.
Quantitative real time PCR
Total RNA samples were obtained using the RNEasy mini kit according to manufacturer's instructions (Qiagen, Valencia, California, USA). Reverse transcription was done with MultiScribe reverse transcriptase (Applied Biosystems, Foster City, California, USA) and random hexamers as per the manufacturer's instructions. The resulting cDNA was then subjected to quantitative real time-PCR as described previously. The data collected from these quantitative PCRs defined a threshold cycle (Ct) of detection for the targets [HGF, insulin-like growth factor (IGF-1), and macrophage-stimulating protein (MSP)] or the control genes (glyceraldehyde 3-phosphate dehydrogenase and hypoxanthine phosphoribosyltransferase 1) in each cDNA sample. To convert the Ct value into a relative abundance of target and control gene per sample, a standard curve was generated for the control gene using serial dilutions of the cDNA sample: an arbitrary value of template was first assigned to the highest standard and then corresponding values were assigned to the subsequent dilutions; these relative values were plotted against the Ct value determined for each dilution, resulting in the generation of the standard curve. The relative amount of target and control genes in each sample was then determined using the comparative Ct method (Applied Biosystems). The ratios of HGF, insulin-like growth factor 1 (IGF-1), and MSP transcripts are normalized by the geometric mean of the two control genes glyceraldehyde 3-phosphate dehydrogenase and hypoxanthine phosphoribosyltransferase 1 and are plotted on the graph.
Assay of cell number
Melanoma cells (1000 cells per well) were plated in triplicate in 96-well plates with 5% FBS and allowed to adhere overnight. After 12-16 h, cells were washed and treated with serum alone or with antibodies, as indicated. Cell numbers were assayed 48 h later using Cell Titer-Glo (Promega catalog# G7571; Madison, Wisconsin, USA), according to the instructions provided by the manufacturer. This assay uses luciferase to measure ATP; because ATP levels are kept constant in living cells, the level is proportional to the number of viable cells.
Western blot analysis
Protein yields were determined by bicinchoninic acid analysis. Proteins were resuspended in SDS-containing sample buffer, heated for 10 min at 701C, and 20 mg/lane, unless otherwise indicated, was resolved by SDS-polyacrylamide gel electrophoresis using 4-12% gradient gels and transferred to Low fluorescence Immobilon-P (Millipore, Billerica, Massachusetts, USA). Membranes were blocked in Odyssey blocking buffer (Licor, Lincoln, Nebraska, USA). Membranes were probed with antibodies listed below in Odyssey blocking buffer with 0.1% Tween 20. Secondary antibodies were conjugated to fluorescent tags, which were detected using the Odyssey Luminescent detector. Blots were analyzed on the Licor Odyssey Infrared imaging system and quantitated using Odyssey application software Version 3.0 (Superior, Nebraska, USA).
Antibodies
Antimouse IgG, IRDye-conjugated purified immunoglobulin from goat (catalog #926-32220, used at 1 : 20 000) and antirabbit IgG, IRDye-conjugated purified immunoglobulin from goat (catalog #926-32211, used at 1 : 20 000) were purchased from LiCor Biosciences. HGFR antibody (catalog #51067, used at 1 : 1000) and IGF-1R antibody (catalog #54274, used at 1 : 500) were purchased from Abcam (Cambridge, Massachusetts, USA). Phosphorylated HGFR [pY1234/1235] antibody (catalog #AF2480, used at 1 : 2500) was purchased from R&D biosystems (Minneapolis, Minnesota, USA). Phosphorylated insulinlike growth factor receptor 1 (IGF-1R) [pY1161] (catalog #101703, used at 1 : 1000) was purchased from Santa Cruz biotechnologies (Santa Cruz, California, USA). P44/ 42 mitogen-activated protein kinase (MAPK) (Erk1/2) antibody (catalog #9107, used at 1 : 2000), phosphory-lated-p44/42 MAPK (Erk1/2) [pThr202/204] (catalog #9101, used at 1 : 1000) were purchased from Cell Signaling Technology (Danvers, Massachusetts, USA). Beta actin (catalog# 600-401-886; used at 1 : 5000) was purchased from VWR (Radnor, Pennsylvania, USA). Two different anti-MSP antibodies (catalog#s AF352 and MAB352) were purchased and tested by R&D Systems. As a control for these antibodies, an immunoglobulin (Ig) G control was purchased from Jackson ImmunoResearch Labs (West Grove, Pennsylvania, USA) (catalog# 0111-000-003). Anti-IGF-1 antibody (catalog# sc-9013), anti-HGF antibody (catalog# sc-7949), and an IgG control (catalog# sc-2027) for these antibodies were purchased from Santa Cruz Biotechnology.
Human individuals
All of the research involving human individuals was approved by the Institutional Review Board of University of Virginia (Human Investigation Committee, HIC 5202 and HIC 10598) in accordance with assurances filed with and approved by the Department of Health and Human Services.
Results
Comprehensive analysis of receptor tyrosine kinases in metastatic melanomas
The phosphorylation of 42 different human RTKs was analyzed in six metastatic melanoma tissues and 17 cell lines derived from metastatic melanomas using phospho-RTK arrays ( Fig. 1 The staining intensity of activated RTKs in the melanoma cell lines was consistently greater than that in melanoma tumor specimens ( Fig. 1a vs. 1c ). The tyrosine phosphatase inhibitor pervanadate was used to treat melanoma cell lines in culture to preserve Tyr phosphorylation, but this was not possible for melanoma tumors before excision and extraction. The inhibitor treatment did not nonspecifically increase Tyr phosphorylation of RTKs in cells. We found the same RTKs activated with or without pervanadate treatment of DM93 cells (not shown). The relatively low level of RTK phosphorylation in tissues was addressed by an amplified detection system to allow comparison with the cell lines. The differences in which RTKs were activated between tumors and cell lines could have been due to nonmelanoma cells in biopsies. The RTKs seen in cell lines but not in the tumors could have been due to the in-vitro culture conditions. We analyzed RTK activation in serum-starved cells using seven of the 17 melanoma cell lines ( Fig. S5 and Table S4 Supplemental digital content http://www.medicine.virginia.edu/ research/research-centers/cell-signaling/faculty/david-l.-brautigan). We found a common set of RTKs that was activated in the cell lines both in the presence and absence of serum: MSPR, HGFR, IGF-1R, FGFR3, ErbB3, and VEGFR3. Even with differences between tumors and cell lines the RTK arrays provided a means to compare the signaling events across multiple samples of melanomas.
We prepared a matrix to compare RTK activation for the melanoma tumors and cell lines (Fig. 2) . We assigned RTKs into four groups (A, B, C, D) based on statistical analysis of differences in their activation status in melanoma. Group A RTKs (12 RTKs in total) were predominantly not active in melanoma cell lines grown in vitro, but some RTKs in this group (e.g. ROR1, ROR2, and Tie-1) were phosphorylated in melanoma tumors. Group B RTKs (19 RTKs in total) were phosphorylated in as few as one, and less than 10, of the 17 cell lines, and in some melanoma tumors. Group B included endothelial growth factor receptor, VEGFR-2, Dtk, and Tie-2. Group C RTKs (five RTKs in total) were phosphorylated in a majority (greater than or equal to 10 of 17) of cell lines (including ErbB4, InsR, and EphA4). Group D RTKs (six RTKs in total) were phosphorylated in more than 80% of the entire set of melanoma cell lines. These receptors included MSPR, HGFR, IGF-1R, VEGFR-3, ErbB3, and FGFR-3. Phospho-HGFR was detected in 14 of 17 (82%) melanoma cell lines, but not in any of seven melanoma tumor samples. Therefore, we also tested HGFR phosphorylation by immunoblotting with a phosphosite-specific (P-Tyr1234/1235) Cell origin Grown in serum   RTK   FGF R4   DM6  DM13  DM93  VMM39  VMM18  DM122  HT144  VMM5A  DM331  SKMel24  VMM1  VMM17  VMM15  VMM14  VMM609  VMM425  VMM917  VMM39  VMM1  VMM5A  VMM17  VMM609  VMM425  VMM917  VMM5AT  VMM17T  VMM39T  VMM609T  VMM425T VMM917T Group Matrix of activated receptor tyrosine kinases (RTKs) in human melanoma cell lines and tissue specimens. The cell origins are plotted along the x-axis and RTKs along the y-axis. RTKs were rank-ordered on the melanoma cell lines with the least activated receptors at the top. Melanoma cell lines grown in serum are shown in blue, serum-starved cell lines in green, and melanoma tumor specimens in lavender. Coloration of the block on the map corresponds to phosphorylation of the RTK on the array. An empty block corresponds with no detectable phosphorylation of the RTK. The black dashed lines delineate the four groups. EGF, endothelial growth factor; FGF, fibroblast growth factor; HGF, hepatocyte growth factor; IGF-1R, insulin-like growth factor receptor 1; M-CSF, macrophage colony-stimulating factor; MSP, macrophage-stimulating protein; PDGF, platelet-derived growth factor; ROR, receptor tyrosine kinase-like orphan receptor; SCF, stem cell factor; VEGF, vascular endothelial growth factor. antibody in 11 cell lines and eight tumors, three of which were tested on the RTK array. By immunoblotting we found phospho-HGFR in the two cell lines DM122 and HT144 and in seven of eight (approximately 88%) tumors (Figs S6a and b Supplemental digital content http:// www.medicine.virginia.edu/research/research-centers/cell-signaling/ faculty/david-l.-brautigan) were tested. We also detected phospho-HGFR by immunoblotting HT144, DM13, and DM93 melanoma cell lines both in the presence and absence of serum ( Fig. S6c Supplemental digital content http://www.medicine.virginia.edu/research/research-centers/cell-sig naling/faculty/david-l.-brautigan). Furthermore, we detected activated HGFR in melanoma cells in a paraffin-embedded formalin-fixed tumor sample by immunohistochemistry (data not shown). On the basis of these observations, we concluded that the MSPR, IGF-1R, HGFR, VEGFR-3, and FGFR-3 RTKs are activated in human melanoma. Our hypothesis was that this occurs through autocrine signaling.
Cell lines
Genotyping of BRAF and NRAS was undertaken on 13 of the 17 cell lines used for the RTK arrays. Of these, nine had BRAF V600E mutation, two had NRAS mutation, and two were wild type for both BRAF and NRAS. The numbers were too small to make any significant conclusions about effects of mutation status on RTK phosphorylation.
Autocrine stimulation of melanoma cell lines
Autocrine activation of VEGF/VEGFR2 and FGF/FGFR in melanoma has already been defined [8] [9] [10] [11] [12] [13] , therefore we focused on testing autocrine stimulation by HGF, IGF-1, and MSP in melanoma. First, quantitative real time-PCR showed mRNA for HGF, IGF-1, and MSP in every one of the 14 melanoma cell lines tested (Fig. 3) . Enzyme-linked immunosorbent assay of cells in medium without added serum showed secretion of IGF-1 in a subset of six tested cell lines, and secretion of MSP in a subset of six tested cell lines (data not shown). Second, because the melanomas were expressing these growth factors, we examined effects of blocking each of these factors with antibodies on cell proliferation in vitro. Addition of anti-IGF-1 antibody to the culture medium blocked melanoma proliferation in all four melanoma cell lines tested (Fig. 4) . In three of the four cell lines, the higher antibody concentrations caused a specific net decrease in number of viable melanoma cells. This suggested to us that depriving the melanoma cells of IGF-1 could be lethal. Addition of anti-HGF antibody to culture medium also blocked melanoma cell proliferation in a dose-dependent manner (Fig. 5 ). In addition, there was a net loss of melanoma cells at the highest antibody concentrations. Addition of a control, nonimmune IgG to the culture medium produced some decrease in melanoma proliferation at the highest concentrations (Figs 4 and 5; white bars). This was despite, at the lower antibody concentrations there being specific inhibition of proliferation by the anti-IGF-1 and HGF antibodies not seen with the IgG control antibody. At the highest concentrations, even though the control antibodies inhibited proliferation, there was a dramatic loss of cells in response to the specific anti-IGF-1 and HGF antibodies. We concluded that neutralization of IGF-1 or HGF by antibodies inhibited proliferation of multiple melanoma cell lines. In contrast, there was no significant reduction in cell proliferation compared with controls by blocking MSP 
Effects of growth factor blockade on receptor phosphorylation and on mitogen-activated protein kinase
The cellular targets of the antiproliferative effects of anti-IGF-1 and anti-HGF were examined by immunoblotting cell extracts with phosphosite-specific antibodies. Phosphorylated IGF-1R and activated MAPK were readily detected in the DM13 melanoma cell line (Fig. 6 ). Phosphorylation of IGF-1R (P-Tyr1161) was extinguished within 6 h of anti-IGF-1 treatment, and the deactivation due to anti-IGF-1 persisted for at least 18 h (Fig. 6a ). Phosphorylation of MAPK remained up to 6 h after IGF-1 blockade, but was not detected at 18 h (Fig. 6a ). Phosphorylation HGFR (P-Tyr1234/1235) was detected by immunoblotting and this staining was eliminated within 6 h of adding anti-HGF antibody to cells (Fig. 6b) . The inhibitory effects persisted for up to 18 h. These results showed that antibodies added to the culture medium indeed interfered with the autocrine activation of the IGF-1 and HGF receptors and the MAPK pathway in melanoma cell lines in vitro.
Discussion
Autocrine growth loops contribute to aberrant RTK signaling in a range of human diseases [29] [30] [31] [32] [33] . Growth factors and their RTKs signal in both autocrine and paracrine manner, and certainly both modes of signaling are important. However, autocrine signaling enables cell autonomy and the ability to independently survive and metastasize. Identification and control of autocrine signaling allows for blocking the invasive phenotype of melanoma, and this is the focus of our discussion. Autocrine signaling including members of the FGF family and their receptors [34] are implicated in melanoma, and our group previously described a VEGF/VEGFR-2 autocrine growth loop in melanoma [8] . However, until now there has been no comprehensive analysis of RTK activation both in melanoma tissue biopsies and in their derivative cell lines. Our comprehensive analysis of 42 RTKs shows that most are not expressed or activated in melanoma. However, a handful of receptors (group D) were activated in almost every melanoma cell line and in melanoma tumors. This group included three RTKs (FGFR-3, VEGFR-3, and HGFR) that act as receptors of previously identified autocrine growth factors in melanoma.
Those results in effect validated our approach and methods. But, in addition we found two other activated RTKs, MSPR and IGF-1R, as potential autocrine-activated RTKs.
It should be noted that the tumor and cell lines had differences in activation of some RTKs. The reason for this is likely to be multifactorial. Lower levels of phosphorylated RTK in cell lines may be due to activated RTKs in stromal cells included in analysis of tissue. Alternatively, higher levels of phosphorylated RTKs in cell lines may be due to a pure clonal tumor population, avoiding the stromal component seen in tissue. In addition, processing of tissue can lead to dephosphorylation of receptor kinases by phosphatases, artificially lowering the levels of transiently phosphorylated RTKs compared with that seen in cell lines. Overall cell lines are a reasonable model in selective cases, but cannot substitute for analysis of tissue. Both systems can be used together to gather a comprehensive view of RTKs in melanoma.
IGF-1R is over expressed in many tumors and is reported to promote proliferation and motility and prevent apoptosis [13, 35] . It has been suggested that IGF-1R is crucial for the viability of melanoma cells in vitro and in vivo [36, 37] .
Treatment of melanoma cells with an IGF-1R antibody resulted in growth arrest and apoptosis [36] . Anti-IGF-1R suppressed the autocrine and paracrine proliferation of several cancer cell lines [38] . In addition, small interfering RNA to IGF-1R strongly inhibits tumor growth in nude mice, suggesting that IGF-1R plays a role in vivo for tumorigenesis [39] . IGF-1 has been shown to be produced by fibroblasts and to act as a paracrine growth factor to stimulate malignant cells that express IGF-1R [40, 41] .
There are no published studies addressing whether IGF-1 is an autocrine growth factor in melanomas. In fact, there is a previous report that melanoma cells do not produce IGF-1 [41] . However, here we show that IGF-1 mRNA is expressed and secreted by melanoma cells and melanoma cell proliferation decreases in response to antibody blockade of IGF-1. Moreover, phosphorylation of the IGF-1 receptor is seen in melanoma cells, and this is eliminated by addition of anti-IGF-1 antibodies to the culture medium. Levels of IGF-1 were not measurable in serum-free medium and thus we conclude that melanoma cells are producing and secreting the IGF-1 that is blocked by the IGF-1 deactivating antibody. The results support our proposal that IGF-1 is a novel autocrine growth factor in melanoma that signals through IGF-1R to support proliferation of cells in vitro. HGF has been implicated in autocrine signaling in melanoma; however, the evidence about its role in melanoma growth and proliferation is incomplete. A previous study showed that six of eight melanoma cell lines tested expressed HGF, but in only two of four cell lines was HGFR activated in the absence of exogenous HGF [23] . To test the hypothesis that HGF is an autocrine factor the two melanoma cell lines were treated with an anti-HGF antibody, which resulted in a decrease in phospho-HGFR, phospho-MAPK, and phospho-AKT. The researchers concluded that HGFR activation was autocrine [23] . Other studies have shown that treatment with HGF results in increased proliferation of human melanocytes in vitro [42] [43] [44] . Our study with more cell lines showed that more than 80% of melanomas have activated HGFR, and we found every cell line tested expressed HGF, both in the presence and absence of serum. The discrepancy between the low incidence of HGFR activation seen on the RTK array and the high incidence of activation on western blot is likely to be due to different phosphorylation sites, different antibody affinities and avidities, or a combination of these three. Given the literature available supporting HGF as an autocrine growth factor, we elected to pursue the study further. By demonstrating reduced cell proliferation after antibody blockade of its ligand HGF, we strengthen the case that HGFR is activated by an autocrine loop.
MSPR is a member of the MET protooncogene family of RTKs that mediates multiple signaling cascades impacting cell motility, adhesion, proliferation, and apoptosis [45] [46] [47] . MSPR is expressed in multiple epithelial cancer cell types: non-small cell lung cancer, hepatocellular carcinomas, pancreatic cancers, and squamous cell carcinomas [45, 48] . We found no reports in the literature of MSPR expression in melanoma cells. However, we discovered that MSPR was activated in every melanoma cell line and tumor using the RTK arrays. The ligand for MSPR is MSP (hepatocyte growth factor-like protein).
There are no reports that MSP is an autocrine growth factor in melanoma. Our antibody experiments suggest that melanoma cells do not depend on MSP as an autocrine factor for proliferation. The question remains, how is MSPR activated in every melanoma cell line and tumor? One possible explanation is that MSPR and HGFR heterodimerize, therefore, autocrine HGF binding to HGFR results in transphosphorylation and activation of MSPR [49] .
Further study of RTK signaling in melanomas may be a fruitful area of research for development of therapies. Work to date has led to the successful introduction of therapeutic agents that target the biological activity of RTKs [50] [51] [52] [53] . For example, we previously found that VEGF is an autocrine growth factor for melanomas that express VEGFR-2 and that the proliferation of those melanomas was inhibited by the anti-VEGF antibody bevacizumab [8] . Bevacizumab is now currently in melanoma clinical trials (NCT00397982 and others). However, our recent studies have indicated that the previously published prevalence of VEGFR-2 expression on melanomas (approximately 90%) may be an overestimate due to nonspecific antibody staining and that the actual percentage of melanomas that express VEGFR-2 is approximately 7% (unpublished). This may explain the low incidence of activated VEGFR-2 seen in the RTK array. Results from this in-vitro study support further 
Beta actin
Signaling effects of antiinsulin-like growth factor 1(IGF-1) or antihepatocyte growth factor (HGF) antibodies in human melanoma cells. (a) DM13 melanoma cells were left untreated or treated with 10 mg/ml of immunoglobulin (Ig) G antibody or the anti-IGF-1 antibody and then incubated for 6 or 18 h, at which time cells were lysed and extracts prepared. Western blot analysis of phospho-IGF-1R, IGF-1R, phospho-mitogen-activated protein kinase (P-MAPK), and MAPK are shown. Beta actin is blotted as a loading control. (b) DM13 melanoma cells were left untreated or treated with 10 mg/ml of IgG antibody or the HGF antibody, and then incubated for 6 or 18 h, at which time cells were lysed and extracts prepared. Western blot analysis of phospho-HGFR, HGFR, phospho-MAPK, and MAPK are shown. Beta actin is blotted as a loading control.
preclinical studies on targeting the HGF/HGFR and IGF-1/IGF-1R autocrine pathways as effective treatments of melanoma in vivo.
